Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination
INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness. METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vacci... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2013 |
Reihe/Periodikum: | Gefenaite , G , Tacken , M , Bos , J , Stirbu-Wagner , I , Korevaar , J C , Stolk , R P , Wolters , B , Bijl , M , Postma , M J , Wilschut , J , Nichol , K L & Hak , E 2013 , ' Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination ' , PLoS ONE , vol. 8 , no. 6 , e66125 . https://doi.org/10.1371/journal.pone.0066125 |
Schlagwörter: | Adjuvants / Immunologic / Adolescent / Adult / Case-Control Studies / Female / Humans / Influenza A Virus / H1N1 Subtype / Influenza Vaccines / Influenza / Human / Male / Middle Aged / Netherlands / Polysorbates / Retrospective Studies / Squalene / Vaccination / Young Adult |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28779412 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/93863b5a-34bc-4347-b5ed-966232153d6b |
INTRODUCTION: Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness. METHODS: VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza was assessed in a matched case-control study (16 pairs). Odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated by using multivariate logistic regression; vaccine effectiveness was estimated as (1-odds ratio)*100%. RESULTS: Vaccine effectiveness against laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia was 98% (84-100%) and 33% (2-54%) respectively. The vaccine did not prevent influenza and/or pneumonia in 18-59 years old subjects, and was 49% (16-69%) effective in 60 years and older subjects. CONCLUSIONS: Even though we cannot entirely rule out that selection bias, residual confounding and/or cross-protection has played a role, the present results indicate that the MF59-adjuvanted A(H1N1)pdm09 influenza vaccine has been effective in preventing laboratory-confirmed A(H1N1)pdm09 influenza and influenza and/or pneumonia, the latter notably in 60 years and older subjects.